{"url":"https://lda.senate.gov/api/v1/filings/7ddac79f-57c8-47dd-bbb7-7eb556e8976c/","filing_uuid":"7ddac79f-57c8-47dd-bbb7-7eb556e8976c","filing_type":"Q3","filing_type_display":"3rd Quarter - Report","filing_year":2022,"filing_period":"third_quarter","filing_period_display":"3rd Quarter (July 1 - Sep 30)","filing_document_url":"https://lda.senate.gov/filings/public/filing/7ddac79f-57c8-47dd-bbb7-7eb556e8976c/print/","filing_document_content_type":"text/html","income":null,"expenses":"250000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"James Sherner","dt_posted":"2022-10-19T17:35:10-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"25 DeForest Ave","registrant_address_2":"Suite 200","registrant_different_address":false,"registrant_city":"Summit","registrant_state":"NJ","registrant_zip":"07901","registrant":{"id":401104248,"url":"https://lda.senate.gov/api/v1/registrants/401104248/","house_registrant_id":null,"name":"SEQIRUS","description":"Manufacturing Influenza vaccines","address_1":"25 Deforest Ave","address_2":"Suite 200","address_3":null,"address_4":null,"city":"Summit","state":"NJ","state_display":"New Jersey","zip":"07901","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"BOB FAY","contact_telephone":"+1 919-577-5000","dt_updated":"2026-07-30T16:50:39.584095-04:00"},"client":{"id":201054,"url":"https://lda.senate.gov/api/v1/clients/201054/","client_id":12,"name":"SEQIRUS","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"NJ","state_display":"New Jersey","country":"US","country_display":"United States of America","ppb_state":"NJ","ppb_state_display":"New Jersey","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2016-01-01"},"lobbying_activities":[{"general_issue_code":"BUD","general_issue_code_display":"Budget/Appropriations","description":"FY2023 appropriations, supplemental appropriations, and FY2023 President's Budget proposals related to pandemic preparedness and seasonal and pandemic influenza preparedness","foreign_entity_issues":"CSL Limited, identified on Registration (LD-1), is the parent company of Seqirus and benefits from the financial success thereof.","lobbyists":[{"lobbyist":{"id":139487,"prefix":"ms","prefix_display":"MS.","first_name":"CHRISTINE","nickname":null,"middle_name":null,"last_name":"FARQUHARSON","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":18,"name":"Office of Management & Budget (OMB)"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Issues related to pandemic preparedness and seasonal and pandemic influenza preparedness.","foreign_entity_issues":"CSL Limited, identified on Registration (LD-1), is the parent company of Seqirus and benefits from the financial success thereof.","lobbyists":[{"lobbyist":{"id":139487,"prefix":"ms","prefix_display":"MS.","first_name":"CHRISTINE","nickname":null,"middle_name":null,"last_name":"FARQUHARSON","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":25,"name":"Defense, Dept of (DOD)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":16,"name":"Natl Security Council (NSC)"},{"id":21,"name":"Office of Science & Technology Policy (OSTP)"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}